Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Table 2

Data on overall survival, progression-free survival, and tumour response of the included studies.

Study	OS (months)		PFS (months)		Overall response rate (%)		Disease control rate (%)		Treatment duration of experimental drug; (months)
	Exp	C	Exp	C	Exp	C	Exp	C
	arm	arm	arm	arm	arm	Arm	arm	Arm
Li et al 2016	6.5	4.7	2.6	1.8	1.7	0	31.8	11	2.9
TAGS 2018	5.7	3.6	2	1.8	4	2	44	14	3
ATTRACTION-2 2017	5.3	4.1	1.61	1.4	11	0	40.3	25	1.9

Exp: Experimental; C: control; NA: Not applicable
Assessed by independent response evaluation committee